Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To study retrospective claims analysis indirectly comparing medication adherence and persistence between intravenous biologics and Oral small-molecule therapies in inflammatory bowel diseases.

Next Previous
Trial Profile

To study retrospective claims analysis indirectly comparing medication adherence and persistence between intravenous biologics and Oral small-molecule therapies in inflammatory bowel diseases.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Aug 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Infliximab (Primary) ; Tofacitinib (Primary) ; Tofacitinib (Primary) ; Vedolizumab (Primary) ; Vedolizumab (Primary)
  • Indications Crohn's disease; Rheumatoid arthritis; Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Takeda

Most Recent Events

  • 09 Aug 2019 New trial record
  • 05 Aug 2019 Results comparing adherence and persistence for vedolizumab and tofacitinib within 12 months after treatment initiation published in the Advances in Therapy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top